The global non-alcoholic steatohepatitis market is expected to reach more than US$ 20 billion by 2025, registering a compound annual growth rate (CAGR) of more than 10% during the forecast period. The increase in the cycles of clinical trials with growing success rates is expected to increase the chances of getting a commercial approval by 2017 which is driving the market. However, the unexplained and complex physiological structure and inefficient diagnostics technology which lengthens the commercialization of non-alcoholic steatohepatitis therapeutics are expected to hamper the growth of the non-alcoholic steatohepatitis market.
In this report, the global non-alcoholic steatohepatitis market is segmented on the basis of therapeutics and region. The market on the basis of therapeutics is segmented into GFT505, obeticholic acid (INT-747), liraglutide (victoza) and simtuzumab, vitamin E, pioglitazone, and placebo. The global non-alcoholic steatohepatitis market is segmented on the basis of key regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is the largest non-alcoholic steatohepatitis market. The market in Asia Pacific is projected to register the highest double digit CAGR during the forecast period. This high growth is attributed to the increasing occurrence of non-alcoholic fatty liver diseases in the densely populated developing countries such as India, South Korea, and China. Furthermore, each region is segmented to provide market revenue for select countries such as the U.S., Canada, the U.K., Germany, China, Japan, India, Brazil, and GCC countries. The report includes a detailed study of the global and regional market for various types of non-alcoholic steatohepatitis and analyzes the variations in the growth of the industry in certain regions.
A glimpse of the report structure is provided in the report description available on the website.
Genfit SA (France), Gilead Sciences (U.S.), Novo Nordisk A/S (Denmark), Intercept Pharmaceuticals (U.S.), Enzo Biochem, Inc. (U.S.), and Raptor Pharmaceutical Corp. (U.S.) are the most active players in the non-alcoholic steatohepatitis market.
This report covers the non-alcoholic steatohepatitis market, in terms of value, and forecasts the market size till 2025. In addition, the report identifies key growth segments and opportunities in the industry. This report also covers detailed competitive outlook including the share and company profiles of the key players in the global non-alcoholic steatohepatitis market. Company profile includes company summary, financial summary, business strategy and planning, SWOT analysis, and current developments.
The deep-dive study on the non-alcoholic steatohepatitis market will help customers with the identification of new market opportunities and targeted promotional plans.
Company Name: Market Research Engine
Contact Person: John Bay
Country: United States
Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact firstname.lastname@example.org